Blauvelt A, Strober B, Langley R, Burge D, Pisenti L, Yassine M, Kavanagh S, Arendt C, Rolleri R, Reich K. Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. J of Skin [Internet]. 2018 Feb. 23 [cited 2024 Jul. 3];2(S1):S16. Available from: https://jofskin.org/33014/index.php/skin/article/view/307